Drug Database
LY

lysine salicylate (lysine salicylate / Dolorosan)

✓ Approved

VUFB · Small Molecule · Small Molecule

What is lysine salicylate?

lysine salicylate is a small molecule developed by VUFB. It is approved for therapeutic indications via unknown.

Drug Profile

Brand Nameslysine salicylate, Dolorosan
CompanyVUFB
Drug ClassSmall Molecule
RouteUnknown
StatusApproved

Therapeutic Indications

lysine salicylate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersAbdominal pain✓ Approved

Related Research Articles

PubMedJournal of computer-aided molecular design2026-08-30

ESM2-Kcr: a novel model combining protein language model and deep learning methods for predicting lysine crotonylation sites.

Liu Kai K, Zhang Shengli S, Ren Jingyi J

Lysine crotonylation (Kcr) is a vital posttranslational modification that plays a significant role in diverse biological processes such as DNA replication, the cell cycle, spermatogenesis, and embryonic stem cell differentiation. Abnormal Kcr levels are associated with multiple diseases including cancer, neurological disorders, and metabolic diseases, making it crucial for understanding disease pathogenesis and progression. In this study, we introduce ESM2-Kcr, a novel computational model designed for predicting Kcr sites. This model integrates the protein language model ESM2 with advanced deep learning techniques including LSTM, multi-head attention mechanism, and CNN. We elaborate on the specific feature extraction contributions of each deep learning module in ESM2-Kcr: LSTM captures the long-distance sequential dependency information of amino acid residues in protein sequences, CNN extracts the local short-range structural and functional features centered on lysine residues, and the multi-head attention mechanism adaptively assigns weight coefficients to key residue positions to highlight Kcr-related critical sequence information and filter out redundant noise. ESM2-Kcr encodes the protein sequences using ESM2_t30_150M_UR50D and further extracts comprehensive features. Through extensive comparisons with other protein language models like ProteinBERT and ProtT5, as well as different models within the ESM2 family, ESM2-Kcr demonstrates superior generalization ability and performance. The ESM2-Kcr model not only enhances our understanding of protein regulation but also holds great potential in identifying disease biomarkers and facilitating drug development. Future research directions may involve extending this framework to other posttranslational modifications. Data and codes are available at https://github.com/liukai23157/ESM2-Kcr .

PubMedEuropean archives of psychiatry and clinical neuroscience2026-08-30

Untargeted plasma metabolomics identifies metabolite signatures associated with suicidality status in chronic schizophrenia.

Wang Lijun L, Lu Chenghao C, Sun Xiaochun X, Sun Wenjie W et al.

Suicide contributes substantially to mortality in schizophrenia, yet metabolic signatures associated with suicidality remain poorly understood. We applied untargeted plasma metabolomics with multivariate modeling to identify plasma metabolic signatures associated with suicidality status and clinical features. We enrolled 146 frequency-matched psychiatric inpatients with chronic schizophrenia: 73 in the suicide-risk (SR) group, defined by current suicidal ideation or suicidal behavior/attempt history at admission, and 73 in the non-suicide-risk (NSR) group. Plasma samples underwent untargeted metabolomic profiling. Discriminating metabolites were identified using orthogonal partial least squares discriminant analysis (OPLS-DA) and Benjamini-Hochberg-adjusted Mann-Whitney U testing (variable importance in projection [VIP] >1.0 and adjusted p <0.05). Stepwise logistic regression with forced clinical covariates generated an exploratory metabolite-based classification model, and Spearman correlations examined associations with Positive and Negative Syndrome Scale (PANSS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores. OPLS-DA identified 70 discriminating metabolites (R2Y = 0.938, Q2Y = 0.650), with nominal enrichment of lysine degradation, glutathione metabolism, phenylalanine/tyrosine/tryptophan biosynthesis, and sphingolipid metabolism. Stepwise regression retained six metabolites associated with SR status (area under the curve [AUC] = 0.774): Sphingosine, 3-OH-TML, Ile-Leu+Leu-Ile, TML, Taurine, and 12-HETE. Gamma-Glu-Thr showed the highest VIP (5.003) and broad clinical correlations. Plasma metabolic differences involving sphingolipid, lysine/carnitine, neuroinflammatory, amino-acid, and glutathione-related pathways were associated with suicidality status in chronic schizophrenia. These exploratory cross-sectional findings require validation in larger longitudinal cohorts using dedicated suicidality assessments.

PubMedMedical mycology journal2026-08-30

A Case of Kerion Celsi due to Trichophyton rubrum Successfully Treated with Fosravuconazole.

Une Chisato C, Ikutama Risa R, Kano Rui R, Kimura Utako U et al.

A male in his seventies presented with multiple erythematous follicular papules on the back, followed by lesions in the occipital region and posterior neck. Fungal examination revealed kerion celsi caused by Trichophyton rubrum. The patient was treated with fosravuconazole 100 mg/day for 8 weeks, and the brush method was negative 1 month later. The oral antifungal medicines approved for treatment of tinea capitis in Japan are limited to itraconazole and terbinafine hydrochloride. However, itraconazole has many contraindicated drugs, and antifungal resistance has recently become a major concern.As the challenge of drug-resistant fungi is expected to become more significant in the future, the clinical benefits of using fosravuconazole L-lysine ethanolate (F-RVCZ) for treating kerion celsi may increase. Our experience suggests that F-RVCZ could be a valuable therapeutic option.

PubMediScience2026-08-30

Atractylenolide I stabilizes HMOX1 to induce ferroptosis and enhance lenvatinib efficacy in hepatocellular carcinoma.

Miao Yangyang Y, Jin Shengjie S, Peng Rui R, Tu Daoyuan D et al.

Lenvatinib resistance limits the therapeutic efficacy of hepatocellular carcinoma (HCC), highlighting the need for effective strategies to enhance treatment response. Atractylenolide I (AT-1), a bioactive compound derived from Atractylodes macrocephala, exhibits antitumor activity, yet its mechanism in HCC remains unclear. Here, we demonstrate that AT-1 suppresses HCC growth by inducing ferroptosis and enhances Lenvatinib efficacy. AT-1 increases intracellular Fe2+ accumulation, lipid peroxidation, and reactive oxygen species, consistent with ferroptotic cell death. Mechanistically, AT-1 directly binds to heme oxygenase-1 (HMOX1) and stabilizes its protein expression by inhibiting ubiquitination at lysine residues K177 and K179, thereby preventing proteasomal degradation. Genetic or pharmacological inhibition of HMOX1 abrogates AT-1-induced ferroptosis and antitumor effects in vitro and in vivo. Notably, AT-1 synergistically enhances Lenvatinib-mediated tumor suppression in HCC models. These findings identify HMOX1 stabilization as a core ferroptosis-regulating mechanism and support AT-1 as a promising adjuvant strategy for HCC therapy.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

DLST Succinylation-Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma.

Li Xuanxuan X, Zhou Peijun P, Peng Xingzhi X, Liu Qixin Q et al.

Metabolic remodeling is one of the hallmarks of malignant tumors, and post-translational modifications of proteins, such as succinylation, play an important role in the process of metabolic remodeling by regulating the function of metabolic enzymes. However, the role of succinylation modifications of key mitochondrial metabolic enzymes in lung adenocarcinoma (LUAD) remains unclear. Here, using succinylation proteomics, it is demonstrated that the succinylation level of lysine 409 (K409) on dihydrolipoamide S-succinyltransferase (DLST) is significantly increased in LUAD. Further, DLST K409 succinylation (K409succ), which is catalyzed by carnitine palmitoyltransferase 1A (CPT1A), can affect oxidative phosphorylation (OXPHOS) and redox homeostasis by regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation. Subsequently, a small-molecule inhibitor SI409-1 that can specifically target DLST K409 has been developed. In vitro and in vivo experiments show that SI409-1 can inhibit the LUAD growth and enhance the sensitivity to cuproptosis inducers. Collectively, these findings provide a novel predictive target and intervention strategy for the clinical diagnosis and treatment of LUAD.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

AARS1-Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer.

Yuan Qin Q, Song Tianbao T, He Yipeng Y, Xia Sihan S et al.

Recurrence and progression remain major clinical challenges in bladder cancer (BC), yet the mechanisms linking glycolysis to persistent malignant states remain incompletely defined. Here, we identify alanyl tRNA synthetase 1 (AARS1) as a clinically relevant driver of aggressive and recurrent BC. AARS1 is upregulated in BC tissues, enriched in muscle invasive and recurrent tumors, and associated with unfavorable survival. Functionally, AARS1 promotes proliferation, epithelial mesenchymal transition, invasion, apoptosis resistance, tumor growth, and lung colonization. Mechanistically, AARS1 enhances phosphoinositide 3 kinase (PI3K) pathway output, glycolytic flux, and lactate production. Increased lactate availability is linked to histone H3 lysine 27 lactylation (H3K27la) enrichment at the hexokinase 2 (HK2) promoter, increased chromatin accessibility, and HK2 transcriptional activation, supporting an HK2 centered metabolic and epigenetic reinforcement program. HK2 perturbation attenuates AARS1 associated glycolytic and malignant phenotypes. Through structure guided screening and surface plasmon resonance validation, we further identified eltrombopag as an AARS1 binding compound that pharmacologically suppressed the AARS1 associated PI3K, glycolysis, lactate, H3K27la, and HK2 program and restrained tumor progression in preclinical models. These findings define an AARS1 associated metabolic and epigenetic program in BC and nominate AARS1 targeting strategies as a direction for further therapeutic development.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about lysine salicylate